Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.

Turk J Haematol · 2017 · PMC5451692 · PMID 27102929

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp=0.060so close (0.05 < p ≤ 0.1)

The mean platelet counts showed a trend to be higher in initial rituximab responders (n=7) compared to non-responders (n=8) (112,201±29,008/mm 3 vs. 33,750±31,332/mm 3 , p=0.060, odds ratio: 7.8; 95% CI 35,212-176,049) ( Figure 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.